These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 9665303

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
    Tenover FC, Baker CN.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
    [Abstract] [Full Text] [Related]

  • 4. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.
    Barry AL, Fuchs PC, Brown SD.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():87-92. PubMed ID: 9511070
    [Abstract] [Full Text] [Related]

  • 5. Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.
    Fuchs PC, Barry AL, Brown SD.
    J Clin Microbiol; 1997 Jan; 35(1):125-31. PubMed ID: 8968893
    [Abstract] [Full Text] [Related]

  • 6. Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae.
    Jorgensen JH, McElmeel ML.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():69-73. PubMed ID: 9511067
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD, Lin ML, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH, Swenson JM, Tenover FC, Barry A, Ferraro MJ, Murray PR, Reller LB.
    J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
    [Abstract] [Full Text] [Related]

  • 12. Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.
    Pankuch GA, Kelly LM, Lin G, Bryskier A, Couturier C, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3270-4. PubMed ID: 14506040
    [Abstract] [Full Text] [Related]

  • 13. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme.
    Reynolds R, Shackcloth J, Felmingham D, MacGowan A, BSAC Extended Working Party on Respiratory Resistance Surveillance.
    J Antimicrob Chemother; 2003 Dec; 52(6):925-30. PubMed ID: 14585864
    [Abstract] [Full Text] [Related]

  • 14. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
    Jamjian C, Barrett MS, Jones RN.
    Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
    [Abstract] [Full Text] [Related]

  • 16. Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH, Swenson JM, Tenover FC, Ferraro MJ, Hindler JA, Murray PR.
    J Clin Microbiol; 1994 Oct; 32(10):2448-59. PubMed ID: 7814481
    [Abstract] [Full Text] [Related]

  • 17. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Castanheira M, Gales AC, Pignatari AC, Jones RN, Sader HS.
    Microb Drug Resist; 2006 Oct; 12(2):91-8. PubMed ID: 16922623
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H.
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.
    Lozniewski A, Lion C, Mory F, Weber M.
    Pathol Biol (Paris); 2000 Jun; 48(5):463-6. PubMed ID: 10949841
    [Abstract] [Full Text] [Related]

  • 20. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
    Barry AL, Fuchs PC, Allen SD, Jorgensen JH, Tenover FC, Murray PR, Hardy DJ, Baker CN.
    J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.